SNGX
Soligenix Inc

12,910
Mkt Cap
$13.92M
Volume
968.00
52W High
$6.23
52W Low
$1.09
PE Ratio
-0.38
SNGX Fundamentals
Price
$1.38
Prev Close
$1.41
Open
$1.40
50D MA
$1.43
Beta
0.48
Avg. Volume
440,224.50
EPS (Annual)
-$4.98
P/B
1.79
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel
Soligenix reports positive Phase 2a extension results for SGX302 gel in psoriasis, showing improved skin scores and strong tolerability.read more...
Benzinga·1mo ago
News Placeholder
More News
News Placeholder
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis Soligenix Announces Top-line Results of the Phase 2a Study of...
PR Newswire·1mo ago
News Placeholder
Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma
Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma Soligenix Achieves Enrollment...
PR Newswire·2mo ago
News Placeholder
Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma
Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma PR Newswire PRINCETON, N.J...
PR Newswire·3mo ago
News Placeholder
Soligenix Logs Best Session In Nearly 2 Months After Safety Win In T-Cell Lymphoma Trial — Traders Eye Multiday Rally
The company said enrollment in its Phase 3 HyBryte study is progressing well, with an interim efficacy analysis planned for the first half of 2026.
Stocktwits·4mo ago
<
...
1
>

Latest SNGX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.